Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





TEMEPHOS								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 3383-96-8; **Chemical Formula:** C16H20O6P2S3
The former OSHA Z tables had no specific limit for exposure to temephos, a cholinesterase-inhibiting insecticide. Temephos was formerly regulated under OSHA’s generic particulate limit of 15 mg/m3. The ACGIH limit is 10 mg/m3 (total dust) as an 8-hour TWA. The proposed PEL was 10 mg/m3 (total particulate), and this is the limit promulgated in the final rule; the 5-mg/m3 limit for the respirable fraction of temephos dust is retained. NIOSH (Ex. 8-47, Table N4) concurs with the selection of these PELs. Temephos may be a white crystalline solid or a viscous brown liquid.
In rats and mice, temephos has an acute oral LD(50) of 400 mg/kg or greater. Various animal species tolerated doses of 10 mg/kg without clinical effect and 1 mg/kg without effect on cholinesterase activity (Gaines, Kimbrough, and Laws 1967/ Ex. 1-553). Laws, Morales, Hayes, and Joseph (1967/Ex. 1-562) revealed that human volunteers consuming oral doses of temephos at levels of either 256 mg/man/day for five days or 64 mg/man/ day for four weeks evidenced no detectable effects on erythro-cyte or plasma cholinesterase levels. Murphy and Cheever (1972/Ex. 1-567) reported that 1 mg of temephos per liter of drinking water produces no effect. These authors found that rat liver carboxylesterases were at least 30 times more sensitive to inhibition from temephos than were rat cholin-esterases. Assuming that human liver carboxylesterases are proportionately more sensitive than cholinesterases, it is estimated that significant inhibition of these carboxylesterases could occur as a result of consuming 2 liters of drinking water containing 1 mg/L of temephos. Although nonspecific liver carboxylesterase is not critical for normal physiologic function, adverse effects on this enzyme could increase the susceptibility of exposed individuals to chemicals and drugs that contain carboxylesterase linkages (ACGIH 1986/Ex. 1-3, p. 557).
The ACGIH derived its limit of 10 mg/m3 TWA for temephos from studies of malathion, which has an acute LD(50) of 2100 mg/kg in rats, or roughly one-half that of temephos. Because humans tolerate 16 mg/day oral doses of malathion without effects on blood cholinesterase levels, the ACGIH believes the 10-mg/m3 limit is appropriate for temephos (ACGIH 1986/Ex. 1-3, p. 557).
OSHA agrees with the ACGIH’s reasoning in this matter and is establishing limits in the final rule of 10 mg/m3 (total particulate) and 5 mg/m3 (respirable fraction) for temephos. The Agency concludes that these limits will protect workers from the significant risk of cholinesterase inhibition and reduction in carboxylesterase activity, which together constitute material health impairments within the meaning of the Act and are potentially associated with exposure to this substance.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue